Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy

Francesco Bandello, Federico Corvi, Carlo La Spina, Lucia Benatti, Lea Querques, Vittorio Capuano, Jonathan Naysan, Xuejing Chen, David Sarraf, Maurizio Battaglia Parodi, Eric Souied, K. Bailey Freund, Giuseppe Querques

Research output: Contribution to journalArticle

Abstract

Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed. Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow-up was 28±19 (12-72) months with a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5±0.3 logMAR; it improved significantly at 1 year (0.3 ±0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6±0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm to 328±104 μm at 1 year (p=0.021) and to 335±127 μm at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation. Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.

Original languageEnglish
JournalBritish Journal of Ophthalmology
DOIs
Publication statusAccepted/In press - Mar 7 2016

Fingerprint

Macular Degeneration
Diabetic Retinopathy
Vascular Endothelial Growth Factor A
Therapeutics
Visual Acuity
Multimodal Imaging
Endothelial Growth Factors
Light Coagulation
Diagnostic Imaging
Medical Records
Referral and Consultation
Injections

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. / Bandello, Francesco; Corvi, Federico; La Spina, Carlo; Benatti, Lucia; Querques, Lea; Capuano, Vittorio; Naysan, Jonathan; Chen, Xuejing; Sarraf, David; Parodi, Maurizio Battaglia; Souied, Eric; Freund, K. Bailey; Querques, Giuseppe.

In: British Journal of Ophthalmology, 07.03.2016.

Research output: Contribution to journalArticle

Bandello, Francesco ; Corvi, Federico ; La Spina, Carlo ; Benatti, Lucia ; Querques, Lea ; Capuano, Vittorio ; Naysan, Jonathan ; Chen, Xuejing ; Sarraf, David ; Parodi, Maurizio Battaglia ; Souied, Eric ; Freund, K. Bailey ; Querques, Giuseppe. / Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy. In: British Journal of Ophthalmology. 2016.
@article{e7854874ee8f42f396b367d6ca560bbf,
title = "Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy",
abstract = "Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed. Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow-up was 28±19 (12-72) months with a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5±0.3 logMAR; it improved significantly at 1 year (0.3 ±0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6±0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm to 328±104 μm at 1 year (p=0.021) and to 335±127 μm at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51{\%}) eyes, moderate NPDR in 14 (34{\%}), severe NPDR in 4 (10{\%}) and inactive proliferative DR in 2 (5{\%}). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation. Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.",
author = "Francesco Bandello and Federico Corvi and {La Spina}, Carlo and Lucia Benatti and Lea Querques and Vittorio Capuano and Jonathan Naysan and Xuejing Chen and David Sarraf and Parodi, {Maurizio Battaglia} and Eric Souied and Freund, {K. Bailey} and Giuseppe Querques",
year = "2016",
month = "3",
day = "7",
doi = "10.1136/bjophthalmol-2016-308400",
language = "English",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy

AU - Bandello, Francesco

AU - Corvi, Federico

AU - La Spina, Carlo

AU - Benatti, Lucia

AU - Querques, Lea

AU - Capuano, Vittorio

AU - Naysan, Jonathan

AU - Chen, Xuejing

AU - Sarraf, David

AU - Parodi, Maurizio Battaglia

AU - Souied, Eric

AU - Freund, K. Bailey

AU - Querques, Giuseppe

PY - 2016/3/7

Y1 - 2016/3/7

N2 - Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed. Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow-up was 28±19 (12-72) months with a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5±0.3 logMAR; it improved significantly at 1 year (0.3 ±0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6±0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm to 328±104 μm at 1 year (p=0.021) and to 335±127 μm at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation. Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.

AB - Purpose To investigate the outcomes of intravitreal antivascular endothelial growth factor (VEGF) therapy in eyes with both neovascular age-related macular degeneration (AMD) and diabetic retinopathy (DR). Methods Patients from four high-volume referral centres who presented with neovascular AMD and DR, and received intravitreal anti-VEGF therapy, were included. Data retrieved from medical records and multimodal imaging were analysed. Results Forty-one eyes of 38 patients (21 male, 17 female; mean age 78±8 years) were enrolled. Median follow-up was 28±19 (12-72) months with a mean of 9.2±7.4 intravitreal anti-VEGF injections per eye were administrated. Best-corrected visual acuity (BCVA) was 0.5±0.3 logMAR; it improved significantly at 1 year (0.3 ±0.3 logMAR; p=0.02) and returned to baseline values at last follow-up visit (0.6±0.4 logMAR; p=0.26). Mean central macular thickness (CMT) significantly decreased from 408±150 μm to 328±104 μm at 1 year (p=0.021) and to 335±127 μm at last follow-up visit (p=0.032). The baseline severity of DR was graded as mild non-proliferative DR (NPDR) in 21 (51%) eyes, moderate NPDR in 14 (34%), severe NPDR in 4 (10%) and inactive proliferative DR in 2 (5%). At last follow-up visit, one eye graded as moderate NPDR improved to mild, one eye graded as severe NPDR improved to mild and one eye graded as severe NPDR was inactivated due to panretinal photocoagulation. Conclusions Outcomes analysis of intravitreal anti-VEGF therapy for eyes with both neovascular AMD and DR showed stabilisation of BCVA and reduction of CMT, along with stable or improved DR stage throughout follow-up.

UR - http://www.scopus.com/inward/record.url?scp=84960899557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960899557&partnerID=8YFLogxK

U2 - 10.1136/bjophthalmol-2016-308400

DO - 10.1136/bjophthalmol-2016-308400

M3 - Article

AN - SCOPUS:84960899557

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

ER -